Since chemo-immunotherapy is now widely used in daily clinical practice in NSCLC patients with PD-L1 expression lower than 50%, we examined if the combination of metformin and CR improved the effect of chemo plus immunotherapy in LKB1-deleted tumors. Here, STK11 is linked to non-small cell lung carcinoma.